Record Nr. UNINA9910624309003321

Titolo Artificial intelligence in COVID-19 / / Niklas Lidstromer and Yonina C.

Eldar, editors

Pubbl/distr/stampa Cham, Switzerland:,: Springer,, [2022]

©2022

ISBN 3-031-08506-X

Descrizione fisica 1 online resource (346 pages)

Disciplina 362.1962414

Soggetti COVID-19 (Disease) - Data processing

Medical informatics

Pandemics - Economic aspects

COVID-19 Epidèmies

Processament de dades Informàtica mèdica

Llibres electrònics

Lingua di pubblicazione Inglese

Formato Materiale a stampa

Livello bibliografico Monografia

Nota di bibliografia Includes bibliographical references and index.

Nota di contenuto Intro -- Foreword -- Preface -- Contents -- About the Editors --

Chapter 1: Introduction to Artificial Intelligence in COVID-19 -- Pandemics -- History of Pandemics -- The COVID-19 Pandemic -- Origins of the COVID-19 Pandemic -- Continuous Fight for Science and Reason -- Modern Tools for Pandemic Control -- A Brief

Chronology of the Chapters of This Book -- Power of Science -- References -- Chapter 2: Al for Pooled Testing of COVID-19 Samples

-- Introduction -- System Model -- The PCR Process -- Mathematical Model -- Pooled COVID-19 Tests -- Recovery from Pooled Tests -- Group Testing Methods for COVID-19 -- Adaptive GT Methods -- Non-

Adaptive GT Methods -- Pooling Matrix -- Noiseless Linear Non-Adaptive Recovery -- Noisy Non-Linear Non-Adaptive Recovery -- Summary -- Compressed Sensing for Pooled Testing for COVID-19 -- Compressed Sensing Forward Model for Pooled RT-PCR -- CS

Algorithms for Recovery -- Details of Algorithms -- Assessment

of Algorithm Performance and Experimental Protocols -- Choice of Pooling Matrices -- Choice of Number of Pools -- Use of Side Information in Pooled Inference -- Comparative Discussion and Summary -- References -- Chapter 3: Al for Drug Repurposing in the Pandemic Response -- Introduction -- Desirable Features of Al for Drug Repurposing in Pandemic Response -- Technical Flexibility and Efficiency -- Clinical Applicability and Acceptability -- Major Al Applications for Drug Repurposing in Response to COVID-19 --Knowledge Mining -- Network-Based Analysis -- In Silico Modelling --IDentif.Al Platform for Rapid Identification of Drug Combinations --Project IDentif.Al -- IDentif.Al for Drug Optimization Against SARS-CoV-2 -- IDentif.Al 2.0 Platform in an Evolving Pandemic -- IDentif.Al as a Pandemic Preparedness Platform -- Use of Real-World Data to Identify Potential Targets for Drug Repurposing. Future Directions -- References -- Chapter 4: Al and Point of Care Image Analysis for COVID-19 -- Introduction -- Motivation for Using Imaging -- Motivation for Using AI with Imaging -- Integration of Imaging with Other Modalities -- Literature Overview -- Chest X-Ray Imaging -- Diagnosis Models -- Prognosis Models -- Use of Longitudinal Imaging -- Fusion with Other Data Modalities --Common Issues with AI and Chest X-Ray Imaging -- Duplication and Quality Issues -- Source Issues -- Frankenstein Datasets --Implicit Biases in the Source Data -- Artificial Limitations Due to Transfer Learning -- Computed Tomography Imaging --Diagnosis Models -- Prognosis Models -- Applications to Regions Away from the Lungs -- Use of Longitudinal Imaging -- Fusion with Other Data Modalities -- Common Issues with Al and Computed Tomography Imaging -- Ultrasound Imaging -- What Can be Observed in LUS --Models Assisting in Interpreting LUS -- Diagnosis Models -- Prognosis Models -- Use of Longitudinal Imaging -- Common Issues with AI and Ultrasound Imaging -- Conclusions -- Success Stories -- Pitfalls to Focus On -- Lessons Learned and Recommendations -- The Next Pandemic -- References -- Chapter 5: Machine Learning and Laboratory Values in the Diagnosis, Prognosis and Vaccination Strategy of COVID-19 -- Introduction -- COVID-19, Machine Learning and Laboratory Values: The State of the Art -- Literature Search Results -- Diagnostic Studies -- Prognostic Studies -- Considerations on the Literature Reviewed -- Heterogeneity in Patient Selection --Laboratory Parameters Used by Machine Learning Models -- Types of Models and Their Validation -- Model Implementation -- The Role of Artificial Intelligence in the Vaccination Strategy Against SARS-COV-2 Through Laboratory Tests -- Real-World Vaccination Strategies --Artificial Intelligence Potentialities -- Conclusions. Appendix 1 -- Diagnostic Papers (D) -- Prognostic Papers (P) --Appendix 2: Tool Online -- References -- Chapter 6: Al and the Infectious Medicine of COVID-19 -- Introduction -- Al and ML for SARS-CoV-2 Early Research Using Pathogen Sequence Data -- Al and ML for Research of SARS-CoV-2 Antivirals -- Al and ML for COVID-19 Infectious Medicine Early Research Using Language Data -- Al and ML in Real World Data Analysis of COVID-19 -- Al and ML in Molecular Diagnostics of COVID-19 -- Al and ML in Image-Based Diagnostics of COVID-19 and Clinical Decision Support -- Al and ML in COVID-19 Medical Care -- Prevention, Infection Risk and Epidemiology -- Treatment and Prognosis -- Conclusions --References -- Chapter 7: Al and ICU Monitoring on the Wake of the COVID-19 Pandemic -- Introduction -- ICU Monitoring Through AI -- ICU Monitoring and AI in Pre-pandemic Times -- The Impact of the COVID-19 Pandemic on the ICU and the Role of AI --

Conclusions -- References -- Chapter 8: Symptom Based Models of COVID-19 Infection Using AI -- Introduction -- Using Machine Learning Methods to Determine Mortality of Patient with COVID-19 -- Using Machine Learning Methods to Detect the Presence of COVID-19 Infection -- Using Machine Learning Methods to Differentiate COVID-19 and Influenza/Common Cold Infections -- Summary, Limitations, Challenges, and Future Applications -- References -- Chapter 9: AI Techniques for Forecasting Epidemic Dynamics: Theory and Practice -- Introduction -- A Review of Model Types and Limits to Forecasting -- Preliminaries -- Model Details -- Metrics for Forecast Evaluations -- AI-Driven Engineering -- An Example of a Real-time Forecasting Model -- Results -- A GNN-Based Spatio-Temporal Model -- Additional Details Regarding the Framework -- Forecasting Performance -- Theoretical Foundations for Forecasting in Network Models -- Overview.

Some Short-Term Forecasting Problems and Their Computational Intractability -- Discussion -- References -- Chapter 10: Regulatory Aspects on AI and Pharmacovigilance for COVID-19 -- What Does Artificial Intelligence Mean According to Legal Definition? -- Al and Health -- The European Union Legal Framework: A Work in Progress -- The Proposed EU Regulation (Artificial Intelligence Act) -- The Use of AI in Research and Developing Medicinal Products and Monitoring Their Quality, Safety and Efficacy -- The Added Value Brought Using Artificial Intelligence in Performing Pharmacovigilance Activities in General and During the COVID-19 Pandemic -- Ethical Issues: A Few Caveats -- The Personal Data Protection Implications --Provisional Conclusions -- Suggested Reading -- Chapter 11: Al and the Clinical Immunology/Immunoinformatics for COVID-19 --Introduction -- Challenge for Traditional Vaccines in COVID-19 --Long Development and Design Period -- Difficulties in Knowing and Optimizing the Efficacy and Side Effects -- Uncertainties with the Development and Other Costs During Production, Storage, and Transportation -- Hard to Tackle Unknown and Emerging Mutations of Viruses -- Existing Al Techniques Help the Traditional Vaccine Development in COVID-19 -- Al Makes the Practical Experimental Results Computational -- Al-Based Computational Tools Can Help the Traditional Vaccine Design -- Al-Based In Silico Vaccine Design -- Our Recently Proposed DeepVacPred Vaccine Design Framework -- Artificial Intelligence for Investigating Viral Evolution and Mutations -- An Algorithmic Information Theoretic Approach to Discover the State Machine Generator Governing the Viral Sequence Structure and Enabling AI Strategies for Viral Mutation Prediction --Characterizing the Temporal Evolution of SARS-CoV-2 in a Continuous Manner.

Detecting Regions Within Viral Sequences Likely to Exhibit Mutations -Summary -- References -- Chapter 12: Al and Dynamic Prediction
of Deterioration in Covid-19 -- Introduction -- COVID-19: A Novel
Disease-Usage of Newer or Older Clinical Decisions Support Systems?
-- Clinical Decisions Support System Stable Parameters/Features Using
Threshold Values -- Patient Deterioration -- General Prediction Scores
-- Early Warning Systems (EWS) -- Al for Prediction of Deterioration -Al Assisted Patient-Specific Risk Prediction -- Al Assisted Prediction
of Critical Illness and Deterioration in COVID-19 Patients -- Mortality
Prediction Models for Covid-19 -- Mortality Prediction Models Using
High-Frequency Data -- Prediction Models for Sepsis -- Explainable
and Interpretable Machine Learning Methods for Clinical Decision
Support Systems -- References -- Chapter 13: Al, Epidemiology
and Public Health in the Covid Pandemic -- Introduction --

Epidemiology: Definition and Purposes -- Epidemiology and Public Health: How They Relate to Each Other and the Concept of One Health -- Individual Health and Population Health -- The Articulation Between Individual and Population Level -- Biomedical and Biopsychosocial Models of Health: Individual, Environmental and Social Determinants of Health -- From Precision Medicine to Precision Public Health -- Epidemiology and Public Health in the Digital Era: Prerequisites -- A Ubiquitous Digitization -- The Evolutions of the Regulatory Framework on Personal Data -- Connected Devices and Equipment Rates -- Digital and E-health Literacy -- Towards a Real Life Use of AI in Epidemiology and Public Health: Some First Examples -- No Data Means No Artificial Intelligence: A Few Words About Data Federation and "New" Types of Data -- Citizens and Patients as Producers, Actor and Manager of Their Own Health.

At the Population Level, Health Surveillance Systems and Al.